Tortugas Neuroscience

Neuroscience biotech that launched publicly in April 2026 with $106M in funding. Developer of TRTL-913, a GABA-A receptor positive allosteric modulator for tinnitus in-licensed from Hansoh Pharmaceutical, part of a four-drug CNS pipeline also including assets licensed from Eisai. Registered a Phase 2a trial for TRTL-913 (NCT07777549) in August 2026, confirming an active tinnitus program with a healthy-volunteer safety/PK arm and an open-label efficacy arm in adults with chronic tinnitus.